^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Singlera Genomics

    i
    Other names: Singlera Genomics
    Related tests:
    Evidence

    News

    2ms
    Singlera Genomics presents results of PDACatch preclinical study at HM Hospitals Annual Early Detection Meeting (GlobeNewswire)
    "Singlera Genomics...presented the results of its initial preclinical study of the PDACatch test, an assay to detect pancreatic cancer in individuals at high risk for the disease, at the HM Hospitals annual Hyper-early Diagnosis in Oncology and its Clinical Management meeting....As part of the preclinical study, Singlera demonstrated that the PDACatch assay could non-invasively retrospectively identify early stage pancreatic cancer in a background population of high-risk patients at high sensitivity."
    Preclinical
    |
    PDACatch assay
    over1year
    Singlera Genomics Receives FDA Breakthrough Device Designation for PDACatch, a Liquid Biopsy Assay for Pancreatic Cancer Detection in High-Risk Individuals (PRNewswire)
    "Singlera Genomics...announced that it had received Breakthrough Device Designation from the Food and Drug Administration (FDA) for its PDACatch assay, a novel DNA methylation-based liquid biopsy assay for the detection of pancreatic adenocarcinoma in individuals at high risk for the disease...Singlera Genomics is in the process of launching a prospective study and clinical trial to further evaluate and obtain pre-market approval for the PDACatch assay."
    Breakthrough therapy designation • FDA event
    |
    PDACatch assay